logo-loader
Shield Therapeutics PLC

Swiss broad label approval 'a further endorsement' of Shield's Feraccru drug

Shield Therapeutics PLC’s (LON:STX) chief executive Carl Sterritt elaborates on the decision by Switzerland’s medical authorities to give approval for its Feraccru iron deficiency drug for all adults with iron deficiency.

He says they'll now be able to market the drug to any adult, whether or not they have been diagnosed with anaemia.

The news comes ahead of the FDA’s decision on whether to grant marketing approval for Feraccru in the US which is due 27 July 2019.

Quick facts: Shield Therapeutics PLC

Price: £1.84

Market: LSE
Market Cap: £215.63 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield's Feraccru likely to command 'high market share and branded pricing'

Capital Network analyst Emma Ulker assesses recent progress made at Shield Therapeutics PLC (LON:STX) with its lead asset Feraccru. The drug's approved and marketed in Europe, with a US approval decision pending for July 27. Feraccru is an oral product absorbed in the gut. It's also...

on 11/5/19

RNS

Director/PDMR Shareholding

6 days, 23 hours ago

Half-year Report

2 weeks, 1 day ago

Notice of Results

3 weeks, 1 day ago

Second Price Monitoring Extn

3 weeks, 6 days ago

Price Monitoring Extension

3 weeks, 6 days ago

Additional Listing

on 2/7/19

Result of AGM

on 13/6/19

2 min read